Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy

Christina Dammers1, Lothar Gremer1,2, Philipp Neudecker1,2, Hans-Ulrich Demuth3, Melanie Schwarten1, Dieter Willbold1,2*

1 Institute of Complex Systems (ICS-6) Structural Biochemistry, Forschungszentrum Jülich, 52425 Jülich, Germany, 2 Institut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, 40225 Düsseldorf, Germany, 3 Fraunhofer Institute for Cell Therapy and Immunology, Dep. Molecular Drug Biochemistry and Therapy, 06120 Halle (Saale), Germany

* d.willbold@fz-juelich.de

Abstract

Alzheimer’s disease (AD) is the leading cause of dementia in the elderly and is characterized by memory loss and cognitive decline. Pathological hallmark of AD brains are intracellular neurofibrillary tangles and extracellular amyloid plaques. The major component of these plaques is the highly heterogeneous amyloid-β (Aβ) peptide, varying in length and modification. In recent years pyroglutamate-modified amyloid-β (pEAβ) peptides have increasingly moved into the focus since they have been described to be the predominant species of all N-terminally truncated Aβ. Compared to unmodified Aβ, pEAβ is known to show increased hydrophobicity, higher toxicity, faster aggregation and β-sheet stabilization and is more resistant to degradation. Nuclear magnetic resonance (NMR) spectroscopy is a particularly powerful method to investigate the conformations of pEAβ isoforms in solution and to study peptide/ligand interactions for drug development. However, biophysical characterization of pEAβ and comparison to its non-modified variant has so far been seriously hampered by the lack of highly pure recombinant and isotope-enriched protein. Here we present, to our knowledge, for the first time a reproducible protocol for the production of pEAβ40 and pEAβ42 from a recombinant precursor expressed in E. coli in natural isotope abundance as well as in uniformly [U-15N]- or [U-13C, 15N]-labeled form, with yields of up to 15 mg/l E. coli culture broth. The chemical state of the purified protein was evaluated by RP-HPLC and formation of pyroglutamate was verified by mass spectroscopy. The recombinant pyroglutamate-modified Aβ peptides showed characteristic sigmoidal aggregation kinetics as monitored by thioflavin-T assays. The quality and quantity of produced pEAβ40 and pEAβ42 allowed us to perform heteronuclear multidimensional NMR spectroscopy in solution and to sequence-specifically assign the backbone resonances under near-physiological conditions. Our results suggest that the presented method will be useful in obtaining cost-effective high-quality recombinant pEAβ40 and pEAβ42 for further physiological and biochemical studies.
Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive decline of cognitive functions and has become the main cause for dementia in the elderly [1, 2]. Pathological hallmarks of AD are intracellular neurofibrillary tangles and the accumulation of extracellular amyloid plaques [3, 4]. Amyloid-β (Aβ) is the major component of these amyloid plaques, produced by cleavage of the amyloid precursor protein through β- and γ-secretases, generating various Aβ isoforms varying in length [5–9]. Besides Aβ isoforms starting with the amino acid (aa) D at position 1 (D1), a significant amount of N-terminally truncated Aβ variants is deposited in the brains of AD patients [10, 11], whereby pyroglutamate (pE)-modified Aβ species were described as the major isoforms [12–15]. Up to 20% of the total Aβ are reported to bear a pE residue at the N-terminus [16]. N-terminally truncated pEAβ(3-x) species, with the first two N-terminal aa D1 and A2 being absent, are dominant isoforms in AD brains [17, 18] and are present in up to equivalent amounts compared to full-length Aβ(1-x) in senile plaques [19–21]. The intracellular amount of pEAβ increases with age and it is predominantly found in lysosomes of neurons and neuroglia [22]. pEAβ plays a central role in triggering neurodegeneration and lethal neurological deficits [23, 24]. Thus, N-terminally modified Aβ isoforms represent highly desirable therapeutic targets and became more important in the recent years [15, 25–27].

Aβ(3-x) can be generated by the removal of the first two aa (D1 and A2) from Aβ(1-x) or by alternative splicing, leading to the N-terminal aa E3. The enzyme glutaminyl cyclase (QC) catalyzes intra-E lactam ring formation involving the N-terminal amino group of E3 and its γ-carboxyl group by dehydration leading to pEAβ [28, 29]. Although N-terminal pE formation is a preferred enzymatic reaction [30], it can also be achieved non-enzymatically [31]. This reaction is accelerated with an N-terminal Q residue as a substrate instead of E [32].

The conversion results in altered biophysical and biochemical properties since: (1) pEAβ shows higher hydrophobicity due to the formation of the N-terminal pE lactam ring and the loss of three charges resulting in increased aggregation propensity [12, 19]. (2) The blocked N-terminus leads to higher stability since it is inaccessible for degradation by aminopeptidases. (3) pEAβ shows faster aggregation kinetics with up to 250-fold acceleration and (4) is also more neurotoxic as compared with corresponding non-N-terminally truncated Aβ species independent of their C-terminal lengths [24, 33–36].

A deeper understanding of the molecular mechanisms of pEAβ formation, aggregation and its structure may provide new insights into the difference compared to Aβ and its role in AD. Structural data from NMR spectroscopy could extend the knowledge of pEAβ pathogenicity and will give information about ligand interactions for rational drug design. However, large amounts of pEAβ are needed for such studies. Principally, peptides up to 100 amino acid residues can be prepared chemically by solid phase synthesis, but when it comes to isotope-enriched peptides this strategy becomes very costly and constant biological activity is not guaranteed since there are often differences in purity between the batches [37].

Here, we report a method for reproducible expression and purification of recombinant pEAβ(3–40) and pEAβ(3–42) with natural isotope abundance, as well as uniformly [U-15N] or [U-13C, 15N]-labeled protein with yields up to 15 mg/l culture based on a previously published protocol for Aβ by Finder, Glockshuber and coworkers [37]. To avoid time and cost consuming enzymatic pE formation by QC, we applied conditions for nonenzymatic pE formation on Aβ (E3Q-x) mutants leading to complete and more rapid pEAβ formation compared to the Aβ (E3-x) species. The chemical and conformational states of the purified pEAβ proteins were characterized biologically by mass spectrometry, thioflavin-T (ThT) assay and solution NMR spectroscopy.
Results and Discussion

Cloning, expression and purification of the mutants A\(\beta\)(E3Q-40/42)

The fusion constructs A\(\beta\)(E3Q-40) and A\(\beta\)(E3Q-42) are based on the recombinant A\(\beta\)(1–42) E. coli derived construct published by Finder, Glockshuber and coworkers [37] consisting of a His\(_6\)-tag, a solubilizing fusion partner (NANP)\(_{19}\), established previously [38], followed by a TEV protease recognition and cleavage site and the A\(\beta\) sequence 3-40/42. E3 was replaced by Q in order to improve the non-enzymatic reaction to pE (Method A in S1 File). The protease recognition site thus is now modified to ENLYFQ\(\downarrow\)Q, where the arrow indicates the cleavage site, leading to Q3 as the N-terminal aa in the resulting A\(\beta\) constructs. Typically, the TEV protease recognition and cleavage site contains a G or a S C-terminal of the TEV protease cut, but as proven previously, an exchange of G or S to Q leads to 90% cleavage efficiency [39]. Thus Q becomes the first aa (Q3) of the cleavage product, which is readily susceptible to non-enzymatic pE formation under mild acidic and elevated temperature conditions. To show the applicability and advantage of this mutation for non-enzymatic pEA\(\beta\) conversion, we additionally produced A\(\beta\)(3–42) starting at the N-terminal position with the original E instead of Q, which in vivo is the primary substrate for QC and is catalytically converted to pEA\(\beta\) but can also be modified non-enzymatically [28]. We found that A\(\beta\)(3–42) converted to pEA\(\beta\) significantly slower than A\(\beta\)(E3Q-42) with Q at the N-terminal position.

Expression of the fusion constructs in E. coli BL21 (DE3) pLysS was obtained at a high cell density of OD\(_{600nm}\) \(\geq\) 1.2. Reducing the temperature after induction to 30°C and expression overnight resulted in a large amount of fusion protein accumulated in inclusion bodies (Fig 1a). Denaturing conditions were necessary to solubilize these inclusion bodies. The first purification step was an IMAC in 8 M GdmCl. One-step washing of the IMAC column with 20 mM imidazole and subsequent elution with 500 mM imidazole was performed to isolate the fusion protein and to remove most of non-specifically bound impurities as analyzed by analytical RP-HPLC (Fig 1b). Typical retention time of fusion A\(\beta\)(E3Q-40) was 5 min and 7 min for fusion A\(\beta\)(E3Q-42). The fusion proteins were further purified using preparative RP-HPLC and lyophilized from aqueous ACN resulting in pure fusion protein determined via SDS-PAGE according to Laemmli [40] (Fig 1c, Method B in S1 File). The following yields per l of cell culture were obtained as shown in Table 1: 200 ± 5 mg for fusion A\(\beta\)(E3Q-40/42) and fusion A\(\beta\)(3–42) in natural abundance, 25 ± 3 mg for \([U^{-\text{15}}\text{N}]\) fusion A\(\beta\)(E3Q-40/42) and 20 ± 3 mg for \([U^{-\text{13}}\text{C, 15}}\text{N}]\) fusion A\(\beta\)(E3Q-40/42).

Next, the lyophilized fusion proteins were analyzed for efficient TEV protease cleavage. It turned out, that high molar ratios of TEV protease were necessary to balance the modified cleavage site, i.e. ENLYFQ\(\downarrow\)Q, instead of ENLYFQ\(\downarrow\)G/S. Enhanced cleavage reaction was achieved by lowering the incubation temperature to 4°C by decreasing the aggregation of the cleaved A\(\beta\) with remaining fusion protein (Method C in S1 File). Most of the fusion A\(\beta\)(E3Q-40/42) were cleaved within 7 h, as proven by analytical RP-HPLC (Fig 2a and 2b). Retention-time of cleaved A\(\beta\)(E3Q-40) was approximately 8.9 min and 12.2 min for A\(\beta\)(E3Q-42). After overnight incubation, cleaved A\(\beta\)(E3Q-42) and A\(\beta\)(3–42) precipitated during the reaction completely, whereas around 50% of A\(\beta\)(E3Q–40) stayed in solution. Precipitates were resolved in 8 M GdmCl for further purification. Chromatograms of preparative HPLC indicate that there was still some fusion protein remaining (Fig 2c) which could be removed by adjusting the gradient as described in the Materials and Methods section. Cleaved A\(\beta\) was separated from the fusion-tag and TEV protease and lyophilized. As the fusion-tag accounts for 70% of the total fusion protein, a maximum of 30 mg target protein per 100 mg fusion protein is theoretically obtainable with 100% cleavage efficiency. In total, approximately 20 mg purified cleaved A\(\beta\)(E3Q-40/42) per 100 mg fusion protein were received.
Conversion to pEAβ40 and pEAβ42

It is known, that N-terminal pE formation from E is a preferred enzymatical reaction [30], but also can be achieved non-enzymatically under mild acidic conditions and increased temperature [31]. However, both enzymatic and non-enzymatic intra-molecular lactam formation with an N-terminal Q residue instead of E is much faster [32]. For this reason, we decided to use the mutant Aβ(E3Q) for spontaneous pE formation and compared it with a construct bearing E3 at the N-terminus. The reaction schemes for the conversion to pE from N-terminal E by dehydration or from N-terminal Q by subtraction of ammonia are shown in Fig 3d. Purified Aβ(E3Q-40), Aβ(E3Q-42) and Aβ(3–42) were dissolved in acetate buffer at pH 3.5 and incubated at 45°C for spontaneous pE formation (Method D in S1 File). Reaction was observed with analytical RP-HPLC at the start of the reaction, after 3 h and after 24 h incubation, respectively (Fig 3a and 3b). Due to the loss of the positively charged hydrophilic amino group, the pE-modified peptides get more hydrophobic resulting in a longer retention time on RP-HPLC. For Aβ(E3Q-40) and Aβ(E3Q-42), the initial peptide peaks eluting at 8.2 or 12.6 min decreased

| Table 1. Yields of intermediates and final purified pEAβ peptides in mg per l culture broth. |
|---------------------------------|---------------------------------|---------------------------------|
| fusion Aβ(E3Q-40) | 205 | 28 | 23 |
| Aβ(E3Q-40) | 42 | 5 | 4.5 |
| pEAβ40 | 15 | 2.3 | 2 |
| fusion Aβ(E3Q-42) | 200 | 24 | 20 |
| Aβ(E3Q-42) | 41 | 4.8 | 4 |
| pEAβ42 | 14 | 2.1 | 1.8 |

doi:10.1371/journal.pone.0139710.t001

Fig 1. Expression and purification of fusion Aβ(E3Q-42) protein in E. coli BL21 (DE3) pLysS. (a) 15% Tris/Glycine-SDS-PAGE analysis of the lysates before IPTG induction (t = 0 h) and after IPTG induction leading to expression of fusion Aβ(E3Q-42) (t = 16 h after induction) at 30°C. (b) Analytical RP-HPLC of IMAC purified fusion Aβ(E3Q-40) (red) and fusion Aβ(E3Q-42) (black) with typical retention times of 5 and 7 min, respectively. (c) 15% Tris/Glycine-SDS-PAGE of IMAC and RP-HPLC purified fusion Aβ(E3Q-42).
over time while new peaks eluting at 9.5 or 15 min emerging due to pE conversion of Aβ(E3Q-40) and Aβ(E3Q-42) appeared. MALDI-mass spectrometry (see below) proved the conversion to the corresponding pE-modified variants. An incubation time of 24 h was appropriate to convert most of Aβ(E3Q-40/42) to pEAβ40 and pEAβ42, respectively, as observable by RP-HPLC analytics (Fig 3a and 3b). Conversion was proven by comparing a non-pE-converted sample of [U-15N]-Aβ(E3Q-40) with [U-15N]-pEAβ40 using MALDI-mass spectrometry (Fig 3e, Method F in S1 File). The calculated averaged mass of [U-15N]-Aβ(E3Q-40) is 4194 Da and 4176 Da for [U-15N]-pEAβ40. Major peaks differing in 18 Da mass were visible, which corresponds to the loss of 15NH3. However, the exact mass of both peptides were 2 Da less than calculated based on the fact that the purified protein is not monoisotopic, but at least 95% of all nitrogen atoms are 15N isotopes. Non-enzymatic conversion of Aβ(3–42) containing the N-terminal E3 to pEAβ42 showed a pronounced decreased efficiency under exactly the same conditions, i.e. 24 h incubation time at 45°C incubation temperature with sodium acetate, pH 3.5, as buffer condition. Only approximately 55% were non-enzymatically converted to pEAβ42 after 24 h incubation time (Fig 3c). Although the incubation time was increased up to 3 days, an improvement of the E to pE conversion was not observable, most likely as a consequence of aggregation. Thus, we proved that the E3Q mutation facilitates and increases the yield of the final pEAβ significantly.

Since pEAβ precipitated completely during conversion the cleavage products were dissolved in 8 M GdmCl for preparative RP-HPLC purification. In this last purification step, it was possible to eliminate remaining impurities like non-pE-converted Aβ(E3Q-40/42). The purity of final pEAβ40 and pEAβ42 was checked by analytical RP-HPLC and by Tris/Tricine-SDS-PAGE [41] and determined to be more than 95% pure (Fig 4a–4c). Final yields of natural abundant pEAβ40 and pEAβ42 were 15 mg/l culture and 14 mg/l culture, respectively. Yields for isotope enriched pEAβ were approximately 2 mg/l culture as shown in Table 1.

Biophysical characterization of pEAβ40 and pEAβ42

Formation of amyloid-aggregates of various amyloidogenic proteins can be easily monitored by the commonly applied ThT assay [42]. Therefore, this assay was used to characterize the
aggregation kinetics of recombinant pEAβ. Aggregation kinetics of 10 μM solutions of pEAβ40 and pEAβ42 were performed in near-physiological aqueous solution (sodium phosphate buffer, pH 7.4) at 37°C (Method G in S1 File). Both recombinant pE-modified Aβ peptides showed the typical properties of Aβ aggregation, i.e. a distinct lag phase, an elongation phase and a stationary phase over a 12 h incubation period (Fig 5). Compared to pEAβ40, pEAβ42 started to aggregate much faster, already before measurement was started, and reaches its stationary phase after 4 h. In contrast, at this time point (4 h) pEAβ40 just starts to overcome its lag phase monitored by ThT assay. Maximum ThT fluorescence intensity for pEAβ40 was observed after 10 h. The observed different aggregation kinetics of pEAβ40 and pEAβ42 can be explained by the fact, that the increased C-terminal length in pEAβ42 compared to pEAβ40 but also, in comparison to wild type Aβ(1-40/42) data, N-terminal deletions enhance aggregation [33, 43].

Fig 3. Non-enzymatic pyroglutamate (pE) formation by acidic and elevated temperature conditions of Aβ(E3Q-40) (a), Aβ(E3Q-42) (b) and wild type Aβ(3-40) (c). Peptides were incubated at 45°C in sodium acetate buffer pH 3.5 for 24 h. Conversion was observed by analytical RP-HPLC with an analytical Zorbax SB-300 C8 column in 30% ACN/ 0.1% TFA at 80°C. Peaks for non-modified peptides decreased while peaks for the pEAβ variants appeared at a longer retention time. (d) Reaction scheme of the conversion of N-terminal E3 or N-terminal Q3 to pE. (e) Mass spectrometry of [U-15N]Aβ(E3Q-40) compared to N-terminally modified [U-15N]pEAβ40. Molecular mass of the peptides differs in 18 Da due to the loss of the 15NH3 group.

doi:10.1371/journal.pone.0139710.g003

Purification of Recombinant Pyroglutamate-Modified Amyloid-β Variants
pEA\(\beta\)40 and pEA\(\beta\)42 were further analyzed by solution NMR spectroscopy. 2D and 3D NMR data were obtained at concentrations varying from 25 to 70 \(\mu\)M in aqueous solution at pH 7.4 and at 5°C (Method H in S1 File). No changes in chemical shifts could be detected within three days for pEA\(\beta\)40 and pEA\(\beta\)42. The NMR assignments were accomplished using BEST-TROSY HNCA+ experiments [44] for pEA\(\beta\)40 and pEA\(\beta\)42. Fig 6a displays an overlay of \(^1\)H,\(^{15}\)N-HSQCs of pEA\(\beta\)40 compared with the non-converted A\(\beta\)(E3Q-40). The loss of two signals from the \(\gamma\)-amino group due to deamination upon lactam ring formation as well as a shift of F4 and the appearance of a new signal of the pE3 peptide bond is the main difference.
The spectra of pEA\(\beta\)42 showed analogous results, the signals for the N-terminal amino group and the \(\gamma\)-amino group of Q3 are missing and a signal derived from the intramolecular pE3 lactam group appears (Fig 6b). However, compared with spectra of recombinant A\(\beta\) (1–40) and A\(\beta\) (1–42) under similar conditions published previously [45–47], the \(^1\)H,\(^{15}\)N-HSQC NMR spectra of pEA\(\beta\)40 and pEA\(\beta\)42 differ slightly from A\(\beta\) (1-40/42). Although in both pEA\(\beta\) species the N-terminal amino acid pE3 and the neighboring F4 are clearly visible, interestingly, R5 and H6 are missing not only in the pE modified peptides but also in the non-converted mutant E3Q, maybe due to the histidine-water proton exchange of H6 at neutral pH. Line-broadening and thus the disappearance of histidine signals were already described [48]. The intermediate acid-base proton exchange rate as well as the different tautomers of H6 might also affect the signal of the neighboring residue R5. D7 is shifted to lower frequency but from residue S8 on till the C-terminus, both NMR spectra for wild type A\(\beta\) (1-40/42) and for pEA\(\beta\)40/42 are nearly identical.

**Conclusion**

The described expression and purification system allows, for the first time, reproducible production of pEA\(\beta\) in natural abundance and isotope-enriched in quantities up to 15 mg/l culture and overcomes the yield and costs limitations to perform reproducible biophysical studies. The purified pEA\(\beta\) peptides (pEA\(\beta\)40 and pEA\(\beta\)42) showed elevated aggregation kinetics compared to A\(\beta\) (1–40) or A\(\beta\) (1–42), but, nonetheless, the monomeric states were suitable for biophysical studies at 5°C for at least three days. Moreover, it was possible to produce [\(^{13}\)C,\(^{15}\)N] pEA\(\beta\)40...
and pEAβ42 in high quality and quantity to perform high resolution NMR spectroscopy in solution state and to assign sequence specific signals of pEAβ40 and pEAβ42 under physiological conditions.

Supporting Information

S1 File. Method A. Cloning of recombinant plasmid encoding Aβ(E3Q-40/42) fusion protein. Method B. Expression and purification of Aβ fusion proteins. Method C. Cleavage of the fusion protein and purification of Aβ. Method D. Conversion to pEAβ40 and pEAβ42. Method E. pEAβ sample preparation. Method F. Mass spectrometry. Method G. Thioflavin-T assay. Method H. NMR spectroscopy.

Acknowledgments

The plasmid encoding the Aβ(1–42) sequence was a generous gift from Prof. Dr. Rudolf Gockshuber (ETH Zürich). We thank Dr. Sabine Metzger (IUF, Düsseldorf) for recording mass spectra. Dr. Kerstin Reiß, Dr. Justin Lecher, Dr. Matthias Stoldt and Maren Thomaier (ICS-6, Forschungszentrum Jülich) are highly acknowledged for scientific advices.

Author Contributions

Conceived and designed the experiments: CD LG PN HUD MS DW. Performed the experiments: CD LG MS PN. Analyzed the data: CD LG MS PN. Wrote the paper: CD MS LG PN DW.

References

1. Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today. 1999; 5: 343–350. PMID: 10431167
2. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009; 66: 435–440. doi: 10.1001/archneurol.2009.15 PMID: 19204149
3. Selkoe DJ. Alzheimer's disease: genotypes, phenotypes, and treatments. Science. 1997; 275: 630–631. PMID: 9019820
4. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012; 148: 1204–1222. doi: 10.1016/j.cell.2012.02.040 PMID: 22424230
5. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 1993; 16: 403–409. PMID: 7504355
6. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell. 1989; 57: 115–126. PMID: 2649245
7. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987; 325: 733–736. PMID: 2881207
8. De Strooper B. Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev. 2010; 90: 465–494. doi: 10.1152/physrev.00023.2009 PMID: 20393191
9. De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010; 6: 99–107. doi: 10.1038/nrneurol.2009.218 PMID: 2039999
10. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A. 1994; 91: 8378–8382. PMID: 8078990
11. Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, et al. beta-Amyloid-(1–42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90: 10836–10840. PMID: 8248178
Purification of Recombinant Pyroglutamate-Modified Amyloid-β Variants

12. Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. J Biol Chem. 2011; 286: 38825–38832. doi: 10.1074/jbc.R111.288308 PMID: 21965666

13. Sullivan CP, Berg EA, Elliott-Bryant R, Fishman JB, McKee AC, Morin PJ, et al. Pyroglutamate-Abeta 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Abeta 11 forming the central core. Neurosci Lett. 2011; 505: 109–112. doi: 10.1016/j.neulet.2011.09.071 PMID: 22001577

14. Gunn AP, Masters CL, Cherny RA. Pyroglutamate-Abeta: role in the natural history of Alzheimer's disease. Int J Biochem Cell Biol. 2010; 42: 1915–1918. doi: 10.1016/j.biocell.2010.08.015 PMID: 20833262

15. Perez-Garmendia R, Gevorkian G. Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer's Disease Immunotherapy. Curr Neuropharmacol. 2013; 11: 491–498. doi: 10.2174/1570159X11311050004 PMID: 24403873

16. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. Acta Neuropathol. 2010; 120: 185–193. doi: 10.1007/s00401-010-0690-1 PMID: 20419305

17. Güntert A, Dobeli H, Bohrmann B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience. 2006; 143: 461–475. PMID: 17008022

18. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochim Biophys Res Commun. 2000; 276: 422–427. PMID: 11027491

19. Kuoy EM, Emmerling MR, Woods AS, Cotter RJ, Roher AE. Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochim Biophys Res Commun. 1997; 237: 188–191. PMID: 9266855

20. De Kimpe L, van Haastert ES, Kaminari A, Zwart R, Rutjes H, Hoozemans JJ, et al. Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Abeta pathology at the lysosome. Age (Dordr). 2013; 35: 673–687.

21. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA. Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009; 118: 487–496. doi: 10.1007/s00401-009-0557-5 PMID: 19547991

22. Meissner JN, Bouter Y, Bayer TA. Neuron Loss and Behavioral Deficits in the TBA42 Mouse Model Expressing N-Truncated Pyroglutamate Amyloid-beta3-42. J Alzheimers Dis. 2015; 45: 471–482. doi: 10.3233/JAD-142868 PMID: 25547635

23. Venkataramani V, Wirths O, Budka H, Hartig W, Kovacs GG, Bayer TA. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-beta in a fraction of amyloid-beta deposits in Alzheimer's disease without cross-reactivity with other protein aggregates. J Alzheimers Dis. 2012; 29: 361–371. doi: 10.3233/JAD-2011-111379 PMID: 22230007

24. Acero G, Manoutcharian K, Vasilievko V, Mungua ME, Govezensky T, Coronas G, et al. Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits. J Neuroimmunol. 2009; 213: 39–46. doi: 10.1016/j.neuroim.2009.06.003 PMID: 19545911

25. Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, et al. Identification of low molecular weight pyroglutamate A(beta) oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem. 2010; 285: 41517–41524. doi: 10.1074/jbc.M110.178707 PMID: 20971852

26. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004; 563: 191–196. PMID: 15063747

27. Schilling S, Niestroj AJ, Rahfeld JU, Hoffmann T, Wermann M, Zunkel K, et al. Identification of human glutaminyl cyclase as a metalloenzyme. Potent inhibition by imidazole derivatives and heterocyclic chelators. J Biol Chem. 2003; 278: 49773–49777. PMID: 14522962

28. Twardzik DR, Peterkofsky A. Glutamic acid as a precursor to N-terminal pyroglutamic acid in mouse plasmacytoma protein (protein synthesis-initiation-immunoglobulins-pyrrolidone carboxylic acid). Proc Natl Acad Sci U S A. 1972; 69: 274–277. PMID: 4400295

29. Chelius D, Jing K, Lueras A, Rehder DS, Dillon TM, Vizel A, et al. Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies. Anal Chem. 2006; 78: 2370–2376. PMID: 16579622
32. Schilling S, Wasternack C, Demuth HU. Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution. Biol Chem. 2008; 389: 983–991. doi: 10.1515/BC.2008.111 PMID: 1897624

33. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Bohm G, et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry. 2006; 45: 12393–12399. PMID: 17029395

34. D’Arrigo C, Tabaton M, Perico A. N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42. Biopolymers. 2009; 91: 861–873. doi: 10.1002/bip.21271 PMID: 19562755

35. Russo C, Salis S, Dolcini V, Venezia V, Song XH, Teller JK, et al. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer’s disease and Down’s syndrome brain. Neurobiol Dis. 2001; 8: 173–180. PMID: 11662251

36. Bayer TA, Wirths O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease. Acta Neuropathol. 2014; 127: 778–801. doi: 10.1007/s00401-014-1287-x PMID: 24803226

37. Finder VH, Vodopivec I, Nitsch RM, Glockshuber R. The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. J Mol Biol. 2010; 396: 9–18. doi: 10.1016/j.jmb.2009.12.016 PMID: 20026079

38. Luhrs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Dobeli H, et al. 3D structure of Alzheimer’s amyloid-beta(1–42) fibrils. Proc Natl Acad Sci U S A. 2005; 102: 17342–17347. PMID: 16293696

39. Kapust RB, Tozser J, Copeland TD, Waugh DS. The P1’ specificity of tobacco etch virus protease. Biochem Biophys Res Commun. 2002; 294: 949–955. PMID: 12074568

40. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227: 680–685. PMID: 5432063

41. Schagger H, von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987; 166: 368–379. PMID: 2449095

42. Bolder SG, Sagis LM, Venema P, van der Linden E. Thioflavin T and birefringence assays to determine the conversion of proteins into fibrils. Langmuir. 2007; 23: 4144–4147. PMID: 17341102

43. Pike CJ, Overman MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem. 1995; 270: 23895–23898. PMID: 7592576

44. Gil-Caballero S, Favier A, Brutscher B. HNCA+, HNCO+, and HNCACB+ experiments: improved performance by simultaneous detection of orthogonal coherence transfer pathways. J Biomol NMR. 2014; 60: 1–9. doi: 10.1007/s10858-014-9847-x PMID: 25056271

45. Weber DK, Sani MA, Gehman JD. A routine method for cloning, expressing and purifying Abeta(1–42) for structural NMR studies. Amino Acids. 2014; 46: 2415–2426. doi: 10.1007/s00726-014-1796-x PMID: 25027618

46. Rezaei-Ghaleh N, Andreetto E, Yan LM, Kapurniotu A, Zweckstetter M. Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polypeptide. PLoS One. 2011; 6: e20289. doi: 10.1371/journal.pone.0020289 PMID: 21633500

47. Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, et al. Solution NMR studies of the A beta(1–40) and A beta(1–42) peptides establish that the Met55 oxidation state affects the mechanism of amyloid formation. J Am Chem Soc. 2004; 126: 1992–2005. PMID: 14971332

48. Day RM, Thalhauser CJ, Sudmeier JL, Vincent MP, Torchilin EV, Sanford DG, et al. Tautomerism, acid-base equilibria, and H-bonding of the six histidines in subtilisin BPN’ by NMR. Protein Sci. 2003; 12: 794–810. PMID: 12649438